Mizuho downgrades Pfizer to neutral, says stock has limited upside from here

Pharmaceutical Pfizer Inc. said that an oral drug for treating COVID-19 could be available by end of 2021.
Soumyabrata Roy | NurPhoto | Getty Images

Investors should trim their bets on Pfizer until the pharmaceutical giant shows what's next for the company after the success of its Covid-19 vaccine, investment firm Mizuho said in a note to clients.

Pfizer beat earnings expectations on the top and bottom lines on Tuesday in a first-quarter report that Mizuho analyst Vamil Divan called "stunning." However, Divan downgraded the stock to neutral from buy on Thursday, saying in a note to clients that it wasn't clear what the next upside driver would be.

More In Street Calls

CNBC ProHere are Tuesday's biggest analyst calls of the day: Tesla, Eli Lilly, Amazon, Apple & more
CNBC ProJPMorgan says buy Amazon as it's set to pass Walmart as the largest U.S. retailer next year
CNBC ProMorgan Stanley downgrades industrial stock Fastenal, citing valuation at an all-time high